Andere talen Apogee Therapeutics, Inc.

Aandelen

APGE

US03770N1019

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 22-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
47,87 ^USD	-2,72%		-10,19%	+71,33%

15/05	Apogee kondigt de dosering aan van de eerste patiënt in de Fase 2-studie naar atopische dermatitis met APG777, een nieuw subcutaan, verlengd halfleven antilichaam tegen anti-IL-13 voor de behandeling van atopische dermatitis en andere ontstekingsziekten	CI
13/05	Het Q1 nettoverlies van Apogee Therapeutics neemt toe	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases	15/05
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases	15/05
Apogee Therapeutics' Q1 Net Loss Widens	13/05
Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results	13/05
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference	06/05
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases	25/03
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease and Other Inflammatory Diseases	25/03
Apogee Therapeutics, Inc.(NasdaqGM:APGE) added to S&P Biotechnology Select Industry Index	18/03
Apogee Closes $483 million Upsized Stock Offering	12/03
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million	12/03
Apogee Therapeutics Prices Upsized $420 Million Share Offering	08/03
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering	08/03
Sector Update: Health Care Stocks Advance Wednesday Afternoon	06/03
Apogee Therapeutics Shares Rise After Jefferies Raises Price Target	06/03
Apogee Therapeutics Unveils $350 Million Share Offering	05/03
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering	05/03
Sector Update: Health Care Stocks Retreating Late Afternoon	05/03
Sector Update: Health Care Stocks Lower Tuesday Afternoon	05/03
Top Midday Gainers	05/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Apogee Therapeutics, Inc.

Aandelen

APGE

US03770N1019

Andere talen

Filters